110 related articles for article (PubMed ID: 23446457)
1. Multiple metastases in a novel LNCaP model of human prostate cancer.
Zou M; Jiao J; Zou Q; Xu Y; Cheng M; Xu J; Zhang Y
Oncol Rep; 2013 Aug; 30(2):615-22. PubMed ID: 23446457
[TBL] [Abstract][Full Text] [Related]
2. Imaging of bioluminescent LNCaP-luc-M6 tumors: a new animal model for the study of metastatic human prostate cancer.
Scatena CD; Hepner MA; Oei YA; Dusich JM; Yu SF; Purchio T; Contag PR; Jenkins DE
Prostate; 2004 May; 59(3):292-303. PubMed ID: 15042605
[TBL] [Abstract][Full Text] [Related]
3. Ectopical expression of human MUC18 increases metastasis of human prostate cancer cells.
Wu GJ; Peng Q; Fu P; Wang SW; Chiang CF; Dillehay DL; Wu MW
Gene; 2004 Mar; 327(2):201-13. PubMed ID: 14980717
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model.
Hsieh CL; Xie Z; Yu J; Martin WD; Datta MW; Wu GJ; Chung LW
Prostate; 2007 May; 67(7):685-91. PubMed ID: 17342752
[TBL] [Abstract][Full Text] [Related]
5. Type I collagen receptor (alpha 2 beta 1) signaling promotes the growth of human prostate cancer cells within the bone.
Hall CL; Dai J; van Golen KL; Keller ET; Long MW
Cancer Res; 2006 Sep; 66(17):8648-54. PubMed ID: 16951179
[TBL] [Abstract][Full Text] [Related]
6. Tumorigenesis and spontaneous metastasis by luciferase-labeled human xenograft osteosarcoma cells in nude mice.
Du L; Xu WT; Fan QM; Tu B; Shen Y; Yan W; Tang TT; Wang Y
Chin Med J (Engl); 2012 Nov; 125(22):4022-30. PubMed ID: 23158137
[TBL] [Abstract][Full Text] [Related]
7. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice.
Pettaway CA; Pathak S; Greene G; Ramirez E; Wilson MR; Killion JJ; Fidler IJ
Clin Cancer Res; 1996 Sep; 2(9):1627-36. PubMed ID: 9816342
[TBL] [Abstract][Full Text] [Related]
8. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.
Sato N; Gleave ME; Bruchovsky N; Rennie PS; Beraldi E; Sullivan LD
Cancer Res; 1997 Apr; 57(8):1584-9. PubMed ID: 9108464
[TBL] [Abstract][Full Text] [Related]
9. Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer.
Sankpal UT; Abdelrahim M; Connelly SF; Lee CM; Madero-Visbal R; Colon J; Smith J; Safe S; Maliakal P; Basha R
Prostate; 2012 Nov; 72(15):1648-58. PubMed ID: 22473873
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Ca(2+)-activated Cl(-) channel ANO1/TMEM16A expression suppresses tumor growth and invasiveness in human prostate carcinoma.
Liu W; Lu M; Liu B; Huang Y; Wang K
Cancer Lett; 2012 Dec; 326(1):41-51. PubMed ID: 22820160
[TBL] [Abstract][Full Text] [Related]
11. An EP4 antagonist ONO-AE3-208 suppresses cell invasion, migration, and metastasis of prostate cancer.
Xu S; Zhang Z; Ogawa O; Yoshikawa T; Sakamoto H; Shibasaki N; Goto T; Wang L; Terada N
Cell Biochem Biophys; 2014 Sep; 70(1):521-7. PubMed ID: 24744183
[TBL] [Abstract][Full Text] [Related]
12. Human kallikrein 7 induces epithelial-mesenchymal transition-like changes in prostate carcinoma cells: a role in prostate cancer invasion and progression.
Mo L; Zhang J; Shi J; Xuan Q; Yang X; Qin M; Lee C; Klocker H; Li QQ; Mo Z
Anticancer Res; 2010 Sep; 30(9):3413-20. PubMed ID: 20944116
[TBL] [Abstract][Full Text] [Related]
13. Expression of core 2 beta1,6-N-acetylglucosaminyltransferase facilitates prostate cancer progression.
Hagisawa S; Ohyama C; Takahashi T; Endoh M; Moriya T; Nakayama J; Arai Y; Fukuda M
Glycobiology; 2005 Oct; 15(10):1016-24. PubMed ID: 15932919
[TBL] [Abstract][Full Text] [Related]
14. Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis.
Saini S; Majid S; Yamamura S; Tabatabai L; Suh SO; Shahryari V; Chen Y; Deng G; Tanaka Y; Dahiya R
Clin Cancer Res; 2011 Aug; 17(16):5287-98. PubMed ID: 21159887
[TBL] [Abstract][Full Text] [Related]
15. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.
Nemeth JA; Harb JF; Barroso U; He Z; Grignon DJ; Cher ML
Cancer Res; 1999 Apr; 59(8):1987-93. PubMed ID: 10213511
[TBL] [Abstract][Full Text] [Related]
16. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
Raffo AJ; Perlman H; Chen MW; Day ML; Streitman JS; Buttyan R
Cancer Res; 1995 Oct; 55(19):4438-45. PubMed ID: 7671257
[TBL] [Abstract][Full Text] [Related]
18. [Characterization of prostate cancer cell lines and their epithelial-mesenchymal transition in subcutaneous tumors].
Zhao L; Jiang YG; Ma J; Luo Y; Zhao JH
Zhonghua Nan Ke Xue; 2011 Apr; 17(4):314-7. PubMed ID: 21548207
[TBL] [Abstract][Full Text] [Related]
19. Obesity-related systemic factors promote an invasive phenotype in prostate cancer cells.
Price RS; Cavazos DA; De Angel RE; Hursting SD; deGraffenried LA
Prostate Cancer Prostatic Dis; 2012 Jun; 15(2):135-43. PubMed ID: 22333686
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor effect of ascorbic acid, lysine, proline, arginine, and epigallocatechin gallate on prostate cancer cell lines PC-3, LNCaP, and DU145.
Roomi MW; Ivanov V; Kalinovsky T; Niedzwiecki A; Rath M
Res Commun Mol Pathol Pharmacol; 2004; 115-116():251-64. PubMed ID: 17564322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
